Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity

A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers

(2018) Jing Wei et al.   CELLULAR IMMUNOLOGY

Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma

(2018) Manoj Kumar Kashyap et al.   Molecular Cancer

Targeting Gas6/TAM in cancer cells and tumor microenvironment

(2018) Guiling Wu et al.   Molecular Cancer

Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy using Mathematical Modeling

(2018) Terisse A. Brocato et al.   Scientific Reports

Aptamer Therapeutics in Cancer: Current and Future

(2018) Yoshihiro Morita et al.   Cancers

Aptamer-based targeted therapy

(2018) Guizhi Zhu et al.   ADVANCED DRUG DELIVERY REVIEWS

Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development

(2018) Tao Wang et al.   BIOTECHNOLOGY ADVANCES

Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics

(2018) Prashant Dogra et al.   Nature Communications

Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes

(2017) Shuaijian Ni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer

(2017) Diana J. Uribe et al.   PLoS One

The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis

(2017) Katharina Staufer et al.   Cell Death & Disease

A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers

(2017) Kazuhiko Haruta et al.   Nucleic Acid Therapeutics

Phospho-AXL is widely expressed in glioblastoma and associated with significant shorter overall survival

(2017) Julia Onken et al.   Oncotarget

Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer

(2017) Jian-Zhong Lin et al.   Oncotarget

Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models

(2017) Pinar Kanlikilicer et al.   Molecular Therapy-Nucleic Acids

Post-SELEX optimization of aptamers

(2016) Shunxiang Gao et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY

Theory and Experimental Validation of a Spatio-temporal Model of Chemotherapy Transport to Enhance Tumor Cell Kill

(2016) Zhihui Wang et al.   PLoS Computational Biology

Quantitative PCR Analysis of DNA Aptamer Pharmacokinetics in Mice

(2015) Katherine Perschbacher et al.   Nucleic Acid Therapeutics

Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer

(2015) Jolanta Krajewska et al.   Expert Review of Clinical Pharmacology

Predictive Modeling of Drug Response in Non-Hodgkin’s Lymphoma

(2015) Hermann B. Frieboes et al.   PLoS One

Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics

(2014) Johan J.F. Verhoef et al.   DRUG DISCOVERY TODAY

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

(2014) Mohammad Hojjat-Farsangi   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs

(2014) Yosuke Hashimoto et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Mechanistic Modeling Identifies Drug-Uptake History as Predictor of Tumor Drug Resistance and Nano-Carrier-Mediated Response

(2013) Jennifer Pascal et al.   ACS Nano

Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer

(2013) Tuan Zea Tan et al.   EMBO Molecular Medicine

Impact of Diffusion Barriers to Small Cytotoxic Molecules on the Efficacy of Immunotherapy in Breast Cancer

(2013) Hiranmoy Das et al.   PLoS One

Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements

(2013) J. Pascal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Axl With an High-affinity Inhibitory Aptamer

(2012) Laura Cerchia et al.   MOLECULAR THERAPY

Silencing Survivin Splice Variant 2B Leads to Antitumor Activity in Taxane-Resistant Ovarian Cancer

(2011) P. E. Vivas-Mejia et al.   CLINICAL CANCER RESEARCH

Targeting Axl and Mer Kinases in Cancer

(2011) A. Verma et al.   MOLECULAR CANCER THERAPEUTICS

Discovery and Development of Therapeutic Aptamers

(2010) P.R. Bouchard et al.   Annual Review of Pharmacology and Toxicology

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

(2009) Oleg Trott et al.   JOURNAL OF COMPUTATIONAL CHEMISTRY

Therapeutic Applications of DNA and RNA Aptamers

(2009) Kristina W. Thiel et al.   OLIGONUCLEOTIDES

Specification of DNA Binding Activity of NF- B Proteins

(2009) F. Wan et al.   Cold Spring Harbor Perspectives in Biology